AN2 Therapeutics, Inc. (ANTX) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
AN2 Therapeutics, Inc. (ANTX) Earnings Overview
As of July 8, 2026, AN2 Therapeutics, Inc. (ANTX) reported trailing twelve-month net income of -$35M, reflecting +32.6% year-over-year growth. The company earned $-1.01 per diluted share over the past four quarters.
Looking at the long-term picture, ANTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$14M in fiscal 2020.
AN2 Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including INSM (-$1.18B net income, -210.5% margin), SPRO ($15M net income, 14.4% margin), PRAX (-$327M net income), ANTX has comparable earnings metrics. Compare ANTX vs INSM →
ANTX Earnings vs Peers
Earnings metrics vs comparable public companies
ANTX Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$35M | +31.5% | -$38M | $-1.16 | - | - |
| 2024 | -$51M | +20.7% | -$55M | $-1.72 | - | - |
| 2023 | -$65M | -58.1% | -$70M | $-2.74 | - | - |
| 2022 | -$41M | -90.1% | -$42M | $-2.79 | - | - |
| 2021 | -$22M | -58.4% | -$22M | $-1.50 | - | - |
| 2020 | -$14M | +59.8% | -$7M | $-0.78 | - | - |
| 2019 | -$34M | - | -$31M | $-0.30 | - | - |
Download Data
Export ANTX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ANTX — Frequently Asked Questions
Quick answers to the most common questions about buying ANTX stock.
What is ANTX earnings per share (EPS)?
ANTX trailing twelve-month (TTM) diluted EPS is $-1.01, reflecting +32.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is AN2 Therapeutics, Inc.'s net income?
AN2 Therapeutics, Inc. (ANTX) trailing twelve-month net income is $-35M as of 2025. Earnings grew +32.6% year-over-year.
Is ANTX profitable?
ANTX is not currently profitable on a TTM basis, reporting a net loss of $-35M. Net margin is N/A. Investors should monitor for a return to profitability.
What is ANTX's earnings growth rate?
ANTX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are ANTX's profit margins?
AN2 Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -52.1%.
Is ANTX growing earnings?
Yes, ANTX earnings are accelerating — EPS growth of +32.6% exceeds the 5-year CAGR of N/A. TTM net income reached $-35M. Earnings momentum is strengthening.
What was ANTX's best earnings year?
AN2 Therapeutics, Inc.'s highest annual net income on record is $-14M, achieved in fiscal year 2020. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were ANTX's earnings last quarter?
ANTX's most recent reported quarter was Q1 2026. Net income was $-10M with diluted EPS of $-0.29. For a full breakdown of all quarters, see the quarterly earnings table on this page.